Chair, Latin America and President, Global Healthcare Practicelschoen@webershandwick.com
Laura is president of the Weber Shandwick Global healthcare practice. She joined the company in 2000 and has built the firm’s healthcare public relations operations. She works closely with its established practices in North America, Europe, Asia and Latin America.
A pioneer in global public relations, she has provided strategic counsel to some of the most visible multinational healthcare-related campaigns, as well as provided ongoing communications support to an array of clients.
Prior to joining the agency, Laura worked for Euro RSCG (1991-2000) and at Burson Marsteller (1983–1991). At Euro RSCG, Laura was the founder and president of Euro RSCG’s healthcare public relations network in the United States.
The international and U.S. clients Laura has counseled include: sanofi-aventis, Eli Lilly, Procter & Gamble, Pfizer, Merck, Wyeth, as well as biotechnology companies such as Gilead, Celgene and Genentech. Her work experience also extends to nonprofit groups. In this area, Laura has worked to support multiple cancer and women’s health groups.
Laura has developed and managed a variety of programs to support pharmaceutical products during pre-launch, launch and post-launch campaigns in the fields of cardiology, immunology, CNS, oncology, anti-infectives, antivirals, metabolic disorders, eye care, orthopedics, pediatrics, women’s health, medical devices. She has also provided direction and counsel to clients in the areas of crisis preparedness, corporate positioning and issues management.
Earlier in her career, Laura worked in broadcasting news and advertising. She earned a bachelor of arts degree in journalism and holds a master’s degree in international relations and business from the University of Pennsylvania. She is a contributor to many professional PR publications, such as Communiqué and Pharmaceutical Marketing Europe. She also lectures on issues related to healthcare communications. Recently, Laura has been advocating the urgency of focusing on ethics to rebuild trust in the pharmaceutical industry.